SERACH RESULTS FOR" Development "
CEO MESSAGE Driven. For Life. SAMSUNG BIOLOGICS 2023. 04 IR Newsletter Dear Investors, This is John Rim, CEO of Samsung Biologics. I would like to begin by expressing my deep gratitude and appreciation for your continued interest and support in Samsung Biologics. Key Highlights Financial Performance (Consolidated) • Steady YoY Sales growth for 13 consecutive quarters since the outbreak of COVID 19 pandemic (Q1'20-Q1'23) CAGR at 52% (20~23) • Revenue: KRW 720.9B (YoY +41%) • Operating Profit: KRW 191.7B (YoY +9%) CMO/CDO • P5 investment in Bio Campus II announced (Mar.) • Strengthened Partnerships with Big Pharmas (CMO, CDO) • Won CDMO Leadership Awards in all 6 Categories (Feb.) • Cum. contract amount reached USD 9.9B Business Expansion • Opening of a regional sales office in New Jersey, US (Mar.) * Investment for ADC manufacturing facilities announced (Jan.) • Strategic investment in Araris Biotech via Life Science Fund Bioepis • Launching of Lucentis biosimilar (SB11) in GER, UK, CA (Mar.) • Positive CHMP Opinion received for Soliris biosimilar (SB12) • Upcoming US launching of Humira Biosimilar (SB5) (Compertitive edge gained by high & low-concentration, prefilled syringe and auto-injector, etc.) Samsung Biologics announced our first quarter financial results, and we are pleased to report quarterly financial performance with consolidated revenue of 720.9 billion won up by 41% YoY and an operating profit of 191.7 billion won up by 9% YoY. Since the beginning of the COVID19 pandemic, sales have increased year on year for 13 consecutive quarters, spurred by significant growth in the CMO business. Based on these solid financial results, we are revising our guidance for our annual revenue growth rate from 10-15%, which we announced this January, to 15%-20% for year 2023. Samsung Biologics has been operating its existing Plants 1 through 3 at full capacity while maximizing operational efficiency and maintaining steady and stable manufacturing output. As a result, we secured CMO contracts with global big pharmas including GSK, Pfizer, and Eli Lilly, to name a few, totaling roughly KRW 500 billion, bringing the total accumulated CMO contract amount to approximately USD 9.9 billion (KRW 13 trillion). We have also been able to enter into a partnership with a large pharmaceutical company in our CDO business and continued to build on our solid track record. Samsung Bioepis, a wholly owned subsidiary of ours since April 2022, has also contributed to our swift top-line growth by broadening revenue streams from the expansion of Lucentis biosimilar (SB11) sales in the United States, and other newly launched markets such as Germany, UK and Canada. Simultaneously, in line with the company's three-dimensional growth strategy, Samsung Biologics continues to augment our differentiated "Super Gap" CDMO competitive edge through expansions in our capacity, geographic presence, and business portfolio. Capacity Expansion | Announcement of investment in Bio Campus II, with the construction of Plant 5 Plant 4 construction has been fully on track, with its 60,000L portion going operational in October last year, and the remaining 180,000L to go live in June of this year. We have already sealed a number of large-scale manufacturing contracts with Plant 4, signing 9 clients on 12 products, and are actively negotiating with 29 additional clients on 44 products. The robust demand seen for outsourced biopharmaceutical manufacturing convinced us that the time has come to proac- tively make this investment as part of our expansion strategy in order to further expand our global CMO market leadership. In this regard, we have decided to invest 1.98 trillion won ($1.51 billion) in the construction of our fifth
development and proactively purchased a plot of land 30% larger than the existing Bio Campus I to lay the groundwork for a large-scale bio complex for future growth. Plant 4 began partial operations in Oct. 2022, and we have secured 11 large-scale manufacturing contracts with 8 global biopharmaceutical companies and are actively negotiating an additional 34 contracts with 26 global major pharmaceutical companies. Based on such strong demand on the horizon, we decided to build our fifth facility even before Plant 4 was fully operational in order to meet our clients' needs in a timely manner. Plant 5 will be the first plant to be housed in Bio Campus II, with a capacity of 180KL, identical to Plant 4's phase 2 large scale design. Bio Campus II - conceptual rendering Plant 5 Construction Plan • Location: Bio Campus II in Songdo, Incheon (Approx. 35.7 million square meters) • Capacity: 180KL (Approx. 9.5 million square meters) • Construction Period (Target): Groundbreaking in Mar. 2023; CGMP ready by Sep. 2025 Expected CAPEX: Approx. KRW 1.98 trillion (incl. production support and utility facilities) With Plant 5, we will integrate simplified and standardized design and processes of our existing plants to save construction time and cost, in addition to optimizing operations. Simultaneously, we aim to introduce even greater competitive advantage and service perfection by incorporating cutting-edge technologies including automated equipment and systems and energy efficiency, while leveraging our deep expertise and know-how gained from the operation of our Bio Campus I plants 1, 2, 3, and 4. Using Plant 5 as a starting point, Samsung Biologics will invest approximately KRW 7 trillion in the development of Bio Campus II, which will include the construction of three additional large-scale mAb manufacturing facilities as well as an Open Innovation center to promote and foster innovative biotechnologies. Furthermore, we will continue to implement various inorganic strategies and pursue portfolio and geographic expansion in order to keep our commitment to being a top-tier biopharmaceutical company. As always, your continuous faith and support in us is greatly appreciated. Sincerely, March 17, 2023 President & CEO John Rim
Dear Investors, This is John Rim, CEO of Samsung Biologics. First and foremost, I would like to express my sincere gratitude and appreciation towards your continued interest and ongoing trust in Samsung Biologics over the past year. In 2022, Samsung Biologics achieved all of its annual targets in existing business divisions and successfully expanded its business scope for long-term, sustainable growth of the company. 2022 Financial Results (Consolidated) Cumulative revenue surpassed KRW 3T *the first and only company among Korean Pharma Revenue: KRW 3,001.3B (YoY +91%) *SBL(separated): KRW 2,437.3B Operating profit: KRW 983.6B (YoY +83%) CMO/CDO Plant 4 partial operations within 23 months of groundbreaking Launched "S-DUALTM and 'DEVELOPICKTM' * Bispecific antibody platform * Drug candidates developability platform Continued orders momentum: Cum. contract amount $9.5B Business Expansion Completion of KRW 3.2T rights offering (Apr.) Full acquisition of Samsung Bioepis (Apr.) Purchase of land for Biocampus II (Jul.) Investments in biotechs via Life Science Fund * Jaguar Gene Therapy (Mar.) and Senda Biosciences (Aug) Biosimilar Business US launch of Lucentis Biosimilar (SB11) (Jun.) FDA approval of high-conc. Humira Biosimilar (SB5) (Aug.) R&D expertise synergizing top-line growth of CDMO biz [A phenomenal fiscal year marked by unprecedented financial performance, with consolidated annual revenue exceeding KRW 3 trillion and an operating profit of around KRW 1 trillion, to be the first and only Korean pharma company to surpass KRW 3 trillion mark in annual sales] Significant and unpredictable volatility from macroeconomic and geopolitical factors has dominated the business environment in 2022. Interest rates were on an upward march, inflation was reaching what appeared at the time to be the generational highs, and exchange rates rose sharply. Despite such an unfavorable business environment, we were able to keep all three plants running at full capacity and maintain industry-leading batch success rates while minimizing product changeover (PCO) based on our operational excellence. As a result, for the first time in a half-year period, we surpassed KRW 1 trillion in revenue and have since broken our own record every quarter. In this regard, we are pleased to announce that we became the first and only Korean pharma company to surpass KRW 3 trillion mark in consolidated annual sales, with an operating profit of around KRW 1 trillion. [Plant 4, the world's largest plant, is on track to be completed within the first half of this year, with active presales activities rapidly locking in capacity.] Last October, Samsung Biologics began partial operations of Plant 4 (60,000 liters), the world's largest bio manufacturing site with a capacity of 240,000 liters, within 23 months after the groundbreaking, which was 6 months faster than the original 29-month timeline. It will be fully operational by the first half of this year, and presales activities have successfully locked in capacity. Prior to the plant's full ramp-up, we signed large-scale manufacturing contract agreements for 11 products with 8 global biopharmaceutical companies, and we are actively communicating with 26 other major clients on approximately 34 products. Based on our key competitive advantages of "speed" and "execution," we will strive to complete Plant 4 construction without a hitch and demonstrate our commitment to meeting client needs in a timely manner in order to solidify our trust-based partnership with our clients. [Taking the leap to become a fully integrated global biopharmaceutical company through active investments and portfolio diversification] In response to rising biopharmaceutical CMO demand, Samsung Biol
Dear Investors, This is John Rim, CEO of Samsung Biologics. I would like to express my deep gratitude and appreciation for your continued interest and support in Samsung Biologics. Q3 Financial Results(consolidated) Revenue : KRW873B(YoY +94%) Operating profit : KRW 324B(YoY +94%) Cumulative revenue surpassed KRW 2T *Outperformed full-year standalone sales of '21(KRW 1.57T) CMO/CDO Plant4 commenced partial operations within 23 months since groundbreaking as planned(Oct.) Proprietary bispecific antibody platform 'S-DUAL'launched(Sep.) Orders momentum: Cum. contract amount of USD 8.5B *173 contracts in total : CMO , CDO Business Expansion Land purchase agreement signed for Biocampus 2(Jul) Biotech investments: USD 15M in Senda Biosciences(Aug.) via Life Science Fund Continued sustainability initiatives with ESG focus * ESG Report 2022 released(Jul.), Ecovadis Gold rating achieved(Sep.) Samsung Bioepis Stably managed operations of Bioepis since acquisition FDA approval of high-concentration Hadllima (SB5) (Aug.) Humira biosimilar Synergy from stable manufacturing and R&D expertise [cumulative revenue of 2 trillion won on a consolidated basis] Today, Samsung Biologics announced our third-quarter financial results. Our operational excellence not only enabled our stable manufacturing capabilities by renning all three plants at full capacity, but it also mximized revenue by maintaining industry-leading batch success rates and minimizing product changeover(PCO). We are pleased to report quarterly revenue of 675 billion won(operating profit of 311 billion won) with consolidate quarterly revenue of 873 billion won and operating profit of 325 billion won. [Plant 4's rapid initial phase of 60,000 liters coming on line in Oct. '22, only 23 months from groundbreaking to GMP-ready, demonstrated our competitive edge in speed as the leading CMO with the highest manufacturing capacity in the world'] Since the third dquarter of 2020, when we began construction on Plant 4, the world's largest bio manufacturing site with 240,000 liters of capacity (approx. 238,000m2 of land), we have signed large-scale manufacturing contract agreements for seven products with five global biopharmaceutical companies prior to the plant's full ramp-up. We are also actively communicating with other major global corporations regarding more than 25 products. As a demonstration of our commitment to meet the needs of clients in a timely manner, we began partial operations of Plant 4 this October as originally announced at ground breaking 23 months ago. Based on our key competitive advantages of 'speed' and 'technology,' Samsung Biologics continues to make history in the biopharmaceutical CMO industry with unprecedented achievements and solidifying our position as a global leading CMO. [Expanding and diversifying our path to become the world's best CDMO] In response to the increasing biopharmaceutical CMO demand, Samsung Biologics signed a purchase agreement with Incheon Metropolitan City in July to acquire an additional parcel of land (357,000m2) approximately 30% larger than our current campus (238,000m2). In addition, we have been expanding our CMO production facilities beyond monoclonal antibodies to accommodate a wide range of industry needs. For example, after 7 months of technology transfer and scale-up, we successfully completed our first commercial scale engineering run of an mRNA vaccine drug substance at our newly-built mRNA manufacturing suite at our Songdo headquarters. With this, we are now fully equipped to provide one-stop, end-to-end services for mRNA vaccines in addition to our flagship CMO services for antibody drugs. Furthermore, Samsung Biologics has been steadily introducing a number of proprietary technology platforms, laying a solid foundation for o
development capabilities, we expect to have our portfolio leadership expanded continuously by pursuing a more flexible and accelerated growth strategy. As an extension of our efforts for sustainable management that began in earnest in 2021, we published our second annual ESG report on July 11th to address a wide range of environmental, social, and governance (ESG) activities that had been carried out in the past year in addition to outlining our plans for the upcoming year. Under our mission of ‘Driven. For a Sustainable Life.', we are continuously improving and committing our resources to create a more sustainable environment, build a healthier society, and implement responsible business activities. We will be steadfastly committed to a wide range of socially and environmentally equitable practices to contribute to society with sustainable growth and development. With our pre-emptive and bold investments backed by solid business execution, Samsung Biologics will continue our path forward from the world's best contract development and manufacturing organization (CDMO) to a fully integrated global bio-pharmaceutical company. I would like to express my deepest gratitude for your consistent interest and trust in Samsung Biologics, and greatly appreciate your continued faith and encouragement to support the perpetual growth and sustainable development of all of our businesses. As always, thank you for your support. Sincerely, John Rim President & CEO, Samsung Biologics
development capabilities and its future growth plans, including novel drug development, etc. SUC CE Thanks to the strong support and interest from shareholders and investors, Samsung Biologics successfully completed the rights offering. In return, we will continue our efforts to take a great leap forward to diversify our business portfolio for sustainable growth and ultimately become a global biopharmaceutical company with great responsibilities to better serve our clients, shareholders, and ultimately society. We greatly appreciate your continued support and interest in Samsung Biologics. Thank you Sincerely, John Rim President and CEO, Samsung Biologics
development capabilities and future performance in novel drug development, and the deal will further deliver Samsung Bioepis' sales growth and operating margin improvements with streamlined operational efficiencies, budget surplus, and cash flow generation. We will continue to be in close communication with Biogen to work collaboratively for our future growth together. For the purchase of Bioepsis shares and to fund the company's strategic growth plans, we have decided to raise the capital of KRW 3 trillion by issuing new shares. By expanding our portfolio, we will evolve to become a global biopharmaceutical company as the next growth engine with great responsibilities to better serve our clients, shareholders, and ultimately society. Our company continues to hold the world's largest biomanufacturing capacity since 2019 and is advancing forward through active investment with unparalleled innovation. We are currently building Plant 4 and will begin construction of Plant 5 this year, which will offer multi-modal product services, venturing into expanding business portfolio for cell and gene therapies and next-gen vaccines utilizing mRNA, PDNA and viral vectors, all at a single site, in addition to mRNA DP and DS manufacturing. We are also in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site. At a time of great momentum for change and advancement, your continued support is indispensable. We ask for your continued trust and support for the success of Samsung Biologics. Thank you. Sincerely, 2022.1.28 CEO and President of Samsung Biologics John Rim
development Platform 'S-Cellerate TM' to offer clients an integrated and seamless drug development solution resulting in accelerated timelines, improving both economics and convenience. We opened our U.S. R&D Lab in San Francisco in 2020, and are planning to add more labs covering the US East Coast and Europe, etc. We have accumulated 87 CDO contracts since 2018, and have been strengthening our seamless one-stop services to clients with high quality and end-to-end capabilities. Pursue Sustainable Growth to a Top-tier Global Bio Pharma CDMOs in the biopharmaceutical industry are projected to grow rapidly at 10% every year, between 2020 and 2026, as a result of increased outsourcing by global pharmaceutical companies, expanded indications and modalities for drugs, and an increase in the number of biotech companies. To seize the opportunity of increased demand for CDMOS, Samsung Biologics' upmost priority this year is to accelerate Plant 4 operation and lock-in pre-sales. Also, within the first of half of this year, we are planning to operate our mRNA drug substance (DS) manufacturing facility, start the construction of Plant 5 (multi modal services), and purchase additional land for Bio Campus II to prepare for Plant 6, open innovation and beyond. Enhancing ESG (Environmental, Social, Governance) Performance As a global biopharmaceutical company, we have enhanced our efforts on ESG management and made progress in various areas. We established an ESG committee within our Board of Directors, published our first Sustainability Report last June, and earned five ISO certificates in BCMS (Business Continuity Management Systems), Safety, Environment, Energy, and Quality. In recognition of our achievements, we received "A" ESG rating from the Korea Corporate Governance Services (KCGS) and were added to the Dow Jones Sustainability World Index, a first for a Korean pharmaceutical company. Last but not least, we have disclosed our mid-term dividend policy and are committed to continuously improve responsible management to enhance shareholder value. We greatly appreciate your continued support and interest in Samsung Biologics. Thank you Sincerely, John Rim President and CEO, Samsung Biologics
development We have also bolstered our efforts on ESG (Environmental, Social and Governance) management and accomplished the following: 5 Global ISO Certifications ISO 22301, ISO 45001, ISO 14001, ISO 50001, ISO 9001 First Sustainability Report Issued Frontier-1.5D Participation ESG Rating 'A Grade' from KCGS Dow Jones Sustainability World Index Inclusion SMI Health Systems Supply Chains Working Group Champion *Sustainable Market Initiative As everyone struggled together to return to normal, Samsung Biologics was proud to serve our part by not only providing high quality, end-to-end CDMO services crucial to our global clients, but also as a responsible member of society for greater sustainability. In 2022, we will continue to put forth our best efforts to pursue a better life for humanity in addition to our continuous growth. In our journey to a brighter future, we will continue to actively communicate with investors to update on our progress and results. This winter feels colder than ever with the pandemic, and we wish you an abundance of joy, health, and a happy year-end and New Year's holidays. Thank you. Sincerely, John Rim President and CEO, Samsung Biologics
Development Platform New Technology Platform for Client Success With S-CellerateTM (Sep. 2021) ESG(Environmental, Social, Governance Climate Risk Management 'Frontier 1.5D Project' as part of 2050 Carbon Neutral Initiative Today Samsung Biologics announced another record-high quarterly financial results Despite higher worldwide uncertainties than ever due to the prolonged COVID-19 pandemic, Samsung Biologics continues to provide a stable supply of pharmaceutical products to our valued clients and receive global regulatory approvals, enabled by strong operational excellence while maintaining a safe work environment for our employees. Thanks to these efforts along with a near-full operation of all three plants, Samsung Biologics achieved an outstanding, record-high third quarter earnings of 450.7 billion won in revenue and 167.4 billion won in operating profit, reflecting an increase of 176.1 billion won and 110.9 billion won compared to the same period last year, respectively. Samsung Biologics launched a technology enabled CDO Platform 'S-Cellerate In addition to recording a strong cumulative backlog of $7.1 billion in signed contracts with large pharmaceutical companies such as Roche and MSD this quarter, Samsung Biologics also successfully launched a CDO Platform 'S-Cellerate TM' in September. Through this technology-enabled platform, clients are able to significantly shorten the biopharmaceutical development period while reducing R&D costs from cell line development to IND submission, and Process Characterization (PC) to Biologics License Application (BLA). Our CDO business has achieved 82 signed contracts within three years since its market entry in 2018, and provides end-to-end services for the development of new drugs throughout the entire process, from preclinical to clinical trials and commercial production. Enhancing ESG (Environmental, Social, Governance) Performance In addition, we are operating a committee to proactively respond to climate change and to manage risks associated with energy use. Through the systematic operation of our ESG management system, we continue to monitor the impact of climate change on our business activities while establishing a goal of reducing greenhouse gas units based on production. In September, we announced our participation in the Frontier -1.5D initiative to develop a climate risk management model in a collaborative effort with industrial sector representatives and the financial Supervisory Service and fulfill our responsibility as a leading company in the global CDMO market. We appreciate your continued support and interest in Samsung Biologics. We will continue to devote ourselves to creating a better future for humanity and enriching human lives through innovation and advanced technology. Thank you Sincerely, John Rim President and CEO, Samsung Biologics
development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon. 3-Dimensional Expansion : Capacity / Geography / Portfolio Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment. In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value. Thank you for your continued support. Sincerely, John Rim President and CEO, Samsung Biologics
development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic. Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2, John Rim President and CEO, Samsung Biologicsand near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services. 2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years: Capacity Expansion By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion Geography Expansion Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects. Scope Expansion Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.) For the Next Decade 3-Dimensional Expansion - Business Expansion & Portfolio Diversification Source : JP Morgan Healthcare Conference 2021 Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance. In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics
development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress. Bio CMO/CDO/CRO Champing 2030 As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020
development and manufacturing according to our strict COVID-19 controls and management system. 2020 Q3 Revenue 2,746B KRW(QoQ 11% DOWN, YoY 49% UP) Operating Profit 565B KRW (QoQ 30% DOWN, YoY 139% UP) Profit Before Incom Tax 737B KRW (QoQ 9% UP, YoY 67% UP) Net Profit 561B KRW (QoQ 8% UP, YoY 27% UP) Manufacturing Contracts and Business Performance 4 additional contracts in Q3 11 cumulative contracts in 2020 thus far plant 4 Expansion(august) S-CHOiceTMLaunched(August) Continuing to Strengthen Business Competitiveness Towards Becoming a Super Value Company In August, we announced our Plant 4 expansion, which will have a capacity of 256,000L. With the Plant 4 expansion Samsung Biologics is proactively responding to changes in the global biopharmaceutical market and is strongly positioned as the global No.1 CMO based on production capacity. applying Super Value Company principles in the CDO(contract development)market, we continue to strengthen our competitive edge. Samsung Biologics successfully launched our own cell line, S-CHOiceTM, in August 2020. The S-CHOiceTM cell line results in shorter production times and price competitiveness for our clients. Additionally, to strengthen client satisfaction and bring our contract development services closer to global clients, we are launching a CDO R&D Center in San Francisco, California on October 29th(KST). I encourage you to attend the online grand opening ceremony of our CDO R&D Center. Please register through the link at the bottom of the letter. Samsung Biologics will contnue to innovate to provide qualiy services for clients to support them in their mission to advance life-saving therapies. Thank you, Tae Han Kim President & CEO, Samsung Biologics October 21, 2020 CEO IR Newsletter 2 뿐만 아니라 글로벌 거점과 고객사 확보 역량 강화를 위해 10월 29일 미국 San Francisco에 CDO R&D 센터를 오픈할 계획입니다. 온라인으로 진행되는 본 행사에 관심 있으신 투자자분들은 메일 하단의 '등록'을 통해 참석하실 수 있습니다. 삼성바이오로직스는 앞으로도 지속적인 혁신을 통해 빠른 속도로 양질의 서비스를 제공하며, 보다 높은 기업가치 창출을 위해 최선을 다하겠습니다. Super Value Company를 향한 삼성바이오로직스의 행보에 투자자 여러분들의 따뜻한 관심과 지속적인 성원을 부탁드립니다. 감사합니다. 2020년10월21일 삼성바이오로직스 대표이사 사장 김태한
Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.